A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-04-29
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00203086
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 472
- Registration Number
- NCT00203034
- Locations
- 🇺🇸
Columbia - Presbyterian Medical Center, New York, New York, United States
🇺🇸Rush - Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Rochester, Rochester, New York, United States
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT00203164
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT00203177
- Locations
- 🇺🇸
Creighton University, Omaha, Nebraska, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
🇺🇸Rush - Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 414
- Registration Number
- NCT00203047
Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics
- Conditions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT00112411
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸Allergy Associates Medical Group, Inc., San Diego, California, United States
Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids
- Conditions
- First Posted Date
- 2005-05-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 415
- Registration Number
- NCT00109668
- Locations
- 🇺🇸
Allergy Research Foundation, Los Angeles, California, United States
🇺🇸Asthma and Allergy Research Center, Sarasota, Florida, United States
🇺🇸Aero Allergy Research Labs of Savannah, Inc, Savannah, Georgia, United States
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Conditions
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT00104273
- Locations
- 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Four Rivers Clinical Research, Paducah, Kentucky, United States
🇺🇸Northern Michigan Neurology, Traverse City, Michigan, United States
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00104091
Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children
- Conditions
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT00094016
- Locations
- 🇺🇸
NorthEast Medical Research Associates, North Dartmouth, Massachusetts, United States
🇺🇸The Asthma and Allergy Center, Papillion, Nebraska, United States
🇺🇸Allergy, Asthma & Dermatology Research Center, Lake Oswego, Oregon, United States